Table 4.
Multivariate Analysis for Experiencing at Least One New Post-HCT Late Effect
| Variable | Autologous Transplantation(n = 493; 171 events) |
Allogeneic Transplantation(n = 594; 400 events) |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age ≥ 50 years | 1.5 | 1.1 to 2.3 | .03 | 1.3 | 1.0 to 1.6 | .03 |
| Female | 1.1 | 0.8 to 1.5 | .61 | 1.5 | 1.2 to 1.9 | .001 |
| Nonwhite* | 0.8 | 0.5 to 1.1 | .16 | 0.9 | 0.7 to 1.1 | .30 |
| Lymphoma† | — | — | 0.9 | 0.6 to 1.4 | .69 | |
| Multiple myeloma‡ | 0.7 | 0.5 to 1.0 | .05 | — | — | |
| Myelodysplastic syndrome§ | — | — | 1.1 | 0.8 to 1.4 | .75 | |
| Other¶ | 1.2 | 0.6 to 2.3 | .67 | 0.7 | 0.4 to 1.2 | .19 |
| Early disease | 0.7 | 0.1 to 5.0 | .68 | 0.9 | 0.7 to 1.2 | .51 |
| Advanced disease | 1.1 | 0.7 to 1.8 | .65 | 1.0 | 0.8 to 1.4 | .78 |
| Total body irradiation in regimen∥ | 0.4 | 0.2 to 0.7 | < .001 | 1.1 | 0.8 to 1.4 | .47 |
| Bone marrow | — | — | 0.9 | 0.6 to 1.2 | .46 | |
| Unrelated donor | — | — | 1.3 | 1.1 to 1.6 | .006 | |
| Female donor/male patient | — | — | 1.2 | 0.9 to 1.6 | .12 | |
| Nonmyeloablative conditioning | — | — | 1.1 | 0.8 to 1.5 | .42 | |
Abbreviations: HCT, hematopoietic cell transplantation; HR, hazard ratio.
Known nonwhite; unknowns are included with reference group.
For autologous transplantation, lymphoma is the reference group; for allogeneic transplantation, leukemia is the reference group.
For allogeneic transplantation, two patients with multiple myeloma are included with the “other” category.
For autologous transplantation, two patients with myelodysplastic syndrome are included with the “other” category.
For autologous transplantation, all except lymphoma and multiple myeloma; for allogeneic transplantation, all except leukemia, lymphoma, and myelodysplastic syndrome.
In patients receiving myeloablative conditioning.